Induction Immunotherapy Has Durable Survival Benefit in Locally Advanced Cervical Cancer Christos Evangelou, MSc, PhD June 29, 2026

https://www.medscape.com/viewarticle/induction-immunotherapy-has-durable-survival-benefit-locally-2026a1000lzq?src= Giving dual checkpoint blockade ahead of chemoradiation yields a high 3-year survival rate for patients with locally advanced cervical cancer, particularly for those with “hot” tumors, according to updated data from the phase 2 COLIBRI-1 trial.